Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene's Profits up 25 Percent in Q1 on Steady Sales

NEW YORK (GenomeWeb News) - Stratagene yesterday said first-quarter revenues were steady as R&D spending dipped nearly 10 percent and profit increased 25 percent.
 
Total receipts for the three months ended March 31, 2007, rose slightly to $24.4 million from $24.3 million year over year.
 
R&D spending fell slightly to $3.1 million from $3.4 million.
 
The company said net income rose to $1.4 million from $1.1 million in the year-ago period.
 
Stratagene had $20.3 million in unrestricted cash and equivalents and $12.6 million in restricted cash at the end of the first quarter.
 
Stratagene did not offer revenue projections for the remainder of 2007.
 
Last month, Stratagene agreed to be acquired by Agilent Technologies for $264 million. Stratagene said its board has approved that deal and it now expects it to close in early June.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.